Arotinolol (INN, marketed under the tradename Almarl) is a medication in the class of mixed alpha/beta blockers.[1] It also acts as a β3 receptoragonist.[2] A 1979 publication suggests arotinolol as having first been described in the scientific literature by Sumitomo Chemical as "β-adrenergic blocking, antiarrhythmic compound S-596".[3]
^Zhao J, Golozoubova V, Cannon B, Nedergaard J (July 2001). "Arotinolol is a weak partial agonist on beta 3-adrenergic receptors in brown adipocytes". Canadian Journal of Physiology and Pharmacology. 79 (7): 585–593. doi:10.1139/cjpp-79-7-585. PMID 11478592.
^Takahashi H, Yoshida T, Nishimura M, Nakanishi T, Kondo M, Yoshimura M (September 1992). "Beta-3 adrenergic agonist, BRL-26830A, and alpha/beta blocker, arotinolol, markedly increase regional blood flow in the brown adipose tissue in anesthetized rats". Japanese Circulation Journal. 56 (9): 936–942. doi:10.1253/jcj.56.936. PMID 1383578.
^Hara Y, Sato E, Miyagishi A, Aono S, Nakatani H (1979). "新しいβ-受容体遮断薬，dl-2-(3'-t-Butylamino-2'-hydroxypropylthio)-4-(5'-carbamoyl-2'-thienyl)-thiazole hydrochloride (S-596) の薬理作用" [Pharmacological properties of dl-2-(3'-t-butylamino-2'-hydroxypropylthio)-4-(5'-carbamoyl-2'-thienyl)thiazole hydrochloride (S-596), a new β-adrenergic blocking agent]. Folia Pharmacologica Japonica (English abstract) (in Japanese). 75 (7): 707–720. doi:10.1254/fpj.75.707. ISSN 1347-8397.
^Wu H, Zhang Y, Huang J, Zhang Y, Liu G, Sun N, et al. (September 2001). "Clinical trial of arotinolol in the treatment of hypertension: dippers vs. non-dippers" (PDF). Hypertension Research. 24 (5): 605–610. doi:10.1291/hypres.24.605. PMID 11675958.
^Lee KS, Kim JS, Kim JW, Lee WY, Jeon BS, Kim D (August 2003). "A multicenter randomized crossover multiple-dose comparison study of arotinolol and propranolol in essential tremor". Parkinsonism & Related Disorders. 9 (6): 341–347. doi:10.1016/S1353-8020(03)00029-4. PMID 12853233.
^(PDF). Sumitomo Dainippon Pharma Co., Ltd. Archived from the original (PDF) on 7 May 2012. Retrieved 6 March 2016.
External linksedit
(in Japanese) Sumitomo Dainippon Pharma Co., Ltd.
(in Japanese) Official Sumitomo Dainippon Pharma Website 2020-07-01 at the Wayback Machine
. Drug Monograph. Drug Information Research Institute. Archived from the original on 2011-07-22.
December 18, 2023
arotinolol, marketed, under, tradename, almarl, medication, class, mixed, alpha, beta, blockers, also, acts, receptor, agonist, 1979, publication, suggests, arotinolol, having, first, been, described, scientific, literature, sumitomo, chemical, adrenergic, blo. Arotinolol INN marketed under the tradename Almarl is a medication in the class of mixed alpha beta blockers 1 It also acts as a b3 receptor agonist 2 A 1979 publication suggests arotinolol as having first been described in the scientific literature by Sumitomo Chemical as b adrenergic blocking antiarrhythmic compound S 596 3 ArotinololClinical dataTrade namesAlmarlOther namesS 596AHFS Drugs comInternational Drug NamesRoutes ofadministrationOral tablets ATC codenoneLegal statusLegal statusIn general Prescription only Pharmacokinetic dataBioavailability2 hoursElimination half life10 hoursIdentifiersIUPAC name RS 5 2 3 tert butylamino 2 hydroxypropyl sulfanyl 1 3 thiazol 4 yl thiophene 2 carboxamideCAS Number68377 92 4 NPubChem CID2239ChemSpider2152 YUNII394E3P3B99KEGGD07465 YChEMBLChEMBL93298 YCompTox Dashboard EPA DTXSID3022619Chemical and physical dataFormulaC 15H 21N 3O 2S 3Molar mass371 53 g mol 13D model JSmol Interactive imageSMILES CC C C NCC CSC1 NC CS1 C2 CC C S2 C O N OInChI InChI 1S C15H21N3O2S3 c1 15 2 3 17 6 9 19 7 21 14 18 10 8 22 14 11 4 5 12 23 11 13 16 20 h4 5 8 9 17 19H 6 7H2 1 3H3 H2 16 20 YKey BHIAIPWSVYSKJS UHFFFAOYSA N Y N Y what is this verify Medical uses editIt is used in the treatment of high blood pressure 4 and essential tremor 5 6 Recommended dosage is 10 to 30 mg per day citation needed References edit Zhao J Golozoubova V Cannon B Nedergaard J July 2001 Arotinolol is a weak partial agonist on beta 3 adrenergic receptors in brown adipocytes Canadian Journal of Physiology and Pharmacology 79 7 585 593 doi 10 1139 cjpp 79 7 585 PMID 11478592 nbsp Takahashi H Yoshida T Nishimura M Nakanishi T Kondo M Yoshimura M September 1992 Beta 3 adrenergic agonist BRL 26830A and alpha beta blocker arotinolol markedly increase regional blood flow in the brown adipose tissue in anesthetized rats Japanese Circulation Journal 56 9 936 942 doi 10 1253 jcj 56 936 PMID 1383578 Hara Y Sato E Miyagishi A Aono S Nakatani H 1979 新しいb 受容体遮断薬 dl 2 3 t Butylamino 2 hydroxypropylthio 4 5 carbamoyl 2 thienyl thiazole hydrochloride S 596 の薬理作用 Pharmacological properties of dl 2 3 t butylamino 2 hydroxypropylthio 4 5 carbamoyl 2 thienyl thiazole hydrochloride S 596 a new b adrenergic blocking agent Folia Pharmacologica Japonica English abstract in Japanese 75 7 707 720 doi 10 1254 fpj 75 707 ISSN 1347 8397 nbsp Wu H Zhang Y Huang J Zhang Y Liu G Sun N et al September 2001 Clinical trial of arotinolol in the treatment of hypertension dippers vs non dippers PDF Hypertension Research 24 5 605 610 doi 10 1291 hypres 24 605 PMID 11675958 nbsp Lee KS Kim JS Kim JW Lee WY Jeon BS Kim D August 2003 A multicenter randomized crossover multiple dose comparison study of arotinolol and propranolol in essential tremor Parkinsonism amp Related Disorders 9 6 341 347 doi 10 1016 S1353 8020 03 00029 4 PMID 12853233 nbsp Almarl アルマール Arotinolol HCl Tablets Full Prescribing Information PDF Sumitomo Dainippon Pharma Co Ltd Archived from the original PDF on 7 May 2012 Retrieved 6 March 2016 External links edit in Japanese Almarl Full Prescribing Information Revised November 2009 Sumitomo Dainippon Pharma Co Ltd in Japanese Official Sumitomo Dainippon Pharma Website Archived 2020 07 01 at the Wayback Machine Arotinolol Hydrochloride Drug Monograph Drug Information Research Institute Archived from the original on 2011 07 22 Retrieved from https en wikipedia org w index php title Arotinolol amp oldid 1174565670, wikipedia, wiki, book, books, library,
